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Background: When novel influenza viruses cause human infections, it is critical to characterize the illnesses, viruses,
and immune responses to infection in order to develop diagnostics, treatments, and vaccines. The objective of the
study was to collect samples from patients with suspected or confirmed A(H1N1)pdm09 infections that could be made
available to the scientific community. Respiratory secretions, sera and peripheral blood mononuclear cells (PBMCs) were
collected sequentially (when possible) from patients presenting with suspected or previously confirmed A(H1N1)
pdm09 infections. Clinical manifestations and illness outcomes were assessed. Respiratory secretions were tested for
the presence of A(H1N1)pdm09 virus by means of isolation in tissue culture and real time RT-PCR. Sera were tested for
the presence and level of HAI and neutralizing antibodies against the A(H1N1)pdm09 virus.
Findings and conclusions: Thirty patients with confirmed A(H1N1)pdm09 infection were enrolled at Baylor College of
Medicine (BCM). Clinical manifestations of illness were consistent with typical influenza. Twenty-eight of 30 had
virological confirmation of illness; all recovered fully. Most patients had serum antibody responses or high levels of
antibody in convalescent samples. Virus-positive samples were sent to J. Craig Venter Institute for sequencing and
sequences were deposited in GenBank. Large volumes of sera collected from 2 convalescent adults were used to
standardize antibody assays; aliquots of these sera are available from the repository. Aliquots of serum, PBMCs and stool
collected from BCM subjects and subjects enrolled at other study sites are available for use by the scientific community,
upon request.
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Influenza is a highly contagious acute respiratory infec-
tion that affects all age groups but has significant mor-
bidity and mortality, especially in the very young and
elderly populations. Influenza is usually a seasonal dis-
ease with high attack rates, short incubation period and
rapid transmission. Periodic infections of humans with
novel strains of influenza raise concerns that a pandemic
of influenza could be unfolding. Novel influenza A
viruses, including H5N1, H7N7, and H9N2 viruses, have
produced human infections in recent years without
evolving into a pandemic. However, in the spring of
2009 a novel influenza A/H1N1 virus [A(H1N1)pdm09]
emerged in Mexico, followed by recognition of* Correspondence: wkeitel@bcm.edu
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reproduction in any medium, provided the orinternational spread to the US [1,2], A pandemic caused
by the A(H1N1)pdm09 virus was declared by the World
Health Organization on June 11, 2009 [3]. When novel
viruses cause infections in humans, it is critical to obtain
samples as soon as possible to identify and characterize
the viruses and the disease they cause, and to under-
stand the host immune response to infection. These
samples are necessary to develop diagnostic tests, treat-
ments, and vaccines for prevention of infection.
The purpose of this study was to collect blood and re-
spiratory samples from subjects who were known or
suspected to have infection caused by the A(H1N1)
pdm09 virus, and to make available to the scientific
community new strains of influenza viruses and other
immunologic reagents to facilitate influenza research.
These samples were used to detect and isolate viruses
for further characterization and to study the adaptive
immune responses following infection. The purpose oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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features of infection among 30 subjects enrolled at
Baylor College of Medicine (BCM) who had confirmed
A(H1N1)pdm09 infection, and to inform the research
community about the availability of samples collected
from subjects enrolled at several study sites, as well as
other A(H1N1)pdm09 resources available through the
National Institutes of Health (NIH).
Methods
Subjects
Male and female subjects of all ages (> 1 day old) who
had an influenza-like illness (subjects who had at least
one respiratory symptom and at least one of the follow-
ing: oral temperature ≥ 100°F; feeling feverish; and/or
close contact with a confirmed case), or who had current
or recent laboratory-confirmed A(H1N1)pdm09 influ-
enza virus infection were invited to participate in the
study. Exclusion criteria included inability or unwilling-
ness of the subject (or parent/guardian) to provide in-
formed consent; influenza known to be caused by a
strain other than the A(H1N1)pdm09 virus; and partici-
pation in another blood donation study. Subjects were
recruited from local healthcare facilities or referred by
their health care providers or through word of mouth.
The study was conducted in accordance with protocols
approved by the BCM Institutional Review Board.
Clinical procedures
Adults provided written informed consent; written paren-
tal informed consent was obtained for subjects under the
age of 18 years. After obtaining informed consent, infor-
mation regarding the patient’s potential source of infection
(exposures) and the illness was collected, along with per-
tinent medical history and demographic information. Per-
mission was requested to review the subjects’ medical
records for additional clinical and laboratory information
(e.g., treatment regimen, results of rapid antigen detection
tests and other laboratory results, if applicable). A targeted
physical examination was performed based on the sub-
ject’s history and/or signs and symptoms at the time of en-
rollment. Samples were collected for virus isolation and
for evaluation of immune responses. Subjects (or parents/
guardians) were given the option to refuse donation of
some of the samples, if desired. Combined nasal wash/
throat swab (NW/TS) specimens were collected for detec-
tion and isolation of A(H1N1)pdm09 influenza viruses.
Venous blood samples for sera and peripheral blood
mononuclear cells (PBMCs) were collected to assess im-
mune responses following infection. The amount of blood
collected varied according to the age of the subject and
whether the illness was acute or convalescent: 5 – 10 mL
from infants; 20 – 60 mL from children; and up to
120 mL was collected from adults. Subjects (and parents/legal guardians) were asked for their permission to be
contacted for up to twelve weeks after initial sampling for
collection of additional information and samples.
The types and frequencies of subsequent sample col-
lection were based on the time since illness onset and
subject consent. NW/TS samples for virus identification
were collected up to 2 weeks after illness onset. If any
sample was positive by PCR, then respiratory samples
were collected again approximately 5 days after the most
recent PCR-positive sample until the results were nega-
tive. For example, if the initial sample collected 2 days
after illness onset was positive, then the subject was re-
sampled at 4–9 days, 10–14 days, and 15–19 days after
illness onset or until the PCR became negative. Acute
blood samples for serum and PBMCs were collected
within 2 weeks of illness onset, and convalescent blood
samples were collected up to 35 days after illness onset.
Symptoms were graded on a scale of 0 to 3, where
0 was absent; 1 was mild (did not interfere with activity);
2 was moderate (interfered somewhat with activity); and
3 was severe (incapacitating). Fever was graded on a
scale of 0–3, where 0 was absent; 1 was mild (100°F-
101.1°F); 2 was moderate (101.2-102°F); and 3 was severe
(≥ 102.1°F). Vomiting was graded as follows: 0 = No
vomiting; 1 = 1–2 episodes/24 hrs; 2 = ≥ 2 episodes/24 hrs;
and 3 = Requires IV hydration. The severity of diarrhea
was graded as follows: 0 = 0–1 loose stools/24 hrs; 1 = 2–3
loose stools/24 hrs; 2 = 4–5 loose stools/24 hrs; and 3 = ≥ 6
loose stools/24 hours or requires IV hydration.
Laboratory procedures
Virus detection and isolation
NW/TS samples collected from subjects presenting within
2 weeks of onset of illness were tested for A(H1N1)pdm09
influenza virus using a real time, reverse transcriptase
polymerase chain reaction (rtRT-PCR) platform with CDC
published primers [4]. In brief, RNA was extracted from
NW/TS specimens with the QIAamp Viral RNA Mini Kit
(Qiagen) in the semiautomated QIAcube unit. Specimens
were tested by rtRT-PCR using specific primers and fluor-
escent Taqman probes for the novel 2009 influenza A/
H1N1 and for seasonal influenza A and B viruses. In
addition, NW/TS samples were inoculated into primary
rhesus monkey kidney (RhMK) tubes for virus isolation.
Hemadsorption (HA) with guinea pig red blood cells
(0.25%) was used to identify the presence of hemadsorbing
viruses including the A(H1N1)pdm09 influenza virus.
HA-positive harvests were tested by rtRT-PCR to identify
the A(H1N1)pdm09 influenza virus.
Serum HAI and neutralizing antibody assays
Assays for A(H1N1)pdm09 -specific serum hemagglu-
tination-inhibiting (HAI) and neutralizing antibodies
were performed as described previously [5]. A fourfold
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between the acute and convalescent serum samples was
considered significant and consistent with a recent infec-
tion. Infection was considered confirmed if at least one
of the following criteria was met: positive rtRT-PCR or
culture on respiratory samples and/or ≥4-fold increase
in HAI or neutralizing antibody titer.
Findings
Forty-one subjects were enrolled at BCM between May
2009 and July 2009. One enrolled child declined to pro-
vide samples and is not included in the analyses. Seven
other subjects had no virological confirmation of infec-
tion: three children with a negative rtRT-PCR test on re-
spiratory samples had no blood samples collected; and
four adults had no detectable HAI or neutralizing anti-
body in acute (N=4) or convalescent (N=3) samples. The
NW/TS samples on these 4 adults were negative for A
(H1N1)pdm09 influenza virus. Of the remaining 33 sub-
jects, 28 had virological confirmation of A(H1N1)pdm09
infection (Figure 1). Eighteen of these were confirmed in
local hospital or health department laboratories prior to
enrollment in the study, and 13 had rtRT-PCR positive
samples after enrollment. Two additional subjects
(SUBID013 and SUBID036) had negative rtRT-PCR and
culture 9 and 12 days after illness onset, respectivelyFigure 1 Virus shedding among patients with confirmed A(H1N1)pdm
which oseltamivir was taken. Asterisk (*) indicates the subject (SUBID009) h(both with confirmed infections in the household); both
of these subjects had significant increases in serum HAI
and/or neutralizing antibody titers. The age distribution
of the 30 subjects who had confirmed infections was as
follows: 5 were < 5 years old; 16 were 5–9 years old; 4
were 10–17 years old; and 5 were > 18 years old.
Three other subjects without virological confirmation
had serological evidence of probable infection: 2 subjects
who had high titers of antibody (HAI and/or neutraliz-
ing antibody titer ≥ 1280) on a single specimen collected
11 and 16 days after illness onset and had household
contact with a confirmed case (the mother and grand-
mother of subject SUBID032); and one with HAI and
neutralizing antibody titers of 28 and 57, respectively, on
day 12 of illness. These 3 subjects are not included in
the analyses.
Demographic features of the 30 subjects with con-
firmed infections are shown in Table 1. An equal
number of males and females with confirmed infec-
tions were enrolled; most were white. The mean age
of these subjects was 12.1 years (range=2 months to
53 years). Seven subjects (23%) reported a history of
asthma, and one subject had a history of hypertension.
No subjects reported a history of diabetes mellitus,
current pregnancy, HIV infection, cancer, immunosup-
pression, tobacco use or other significant neurological,09 infections. Note: The bracketed line indicates the period during
ad a negative culture result at Day 1; PCR result not available for Day 1.
Table 1 Demographic characteristics of subjects with
confirmed A(H1N1)pdm09 infections
Sex Male Female
15 (50) * 15 (50)
Ethnicity Non-Hispanic Hispanic
22 (73) 8 (27)
Race White Asian, Black, or Multiracial
27 (90) 1 (3) each
Age (years) Mean (SD) Median (Range)
12.1 (10.5) 9.1 (2 months, 53 years)
* Number (percent).








≥4-Fold Rise in Titer (Acute +
convalescent sera available)
15 8 11
Acute Titer ≥ 20; No Significant
Rise in Titer
15 6 2
Convalescent Titer ≥ 20
(No acute sample)
10 9 9
Titer < 20 in All Sample(s) 26 2 2
Titer ≥ 40 in Acute and/or
Convalescent Sample
26 18 20
No Data 4 4 4
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jects had received a seasonal influenza vaccine during
the fall of 2008.
Virological and serological features of infection
The results of sequential culture and PCR assays of re-
spiratory secretions are shown in Figure 1. A bracketed
line indicates the period during which antiviral therapy
with oseltamivir was administered. Most subjects were
treated: 21/30 received a 5-day course of therapy (dosage
based on weight) that was started within 3 days after
symptom onset, with the exception of one subject whose
treatment was started on day 5 of illness. One additional
subject developed culture-positive symptomatic disease
while receiving antiviral prophylaxis (SUBID012; 75 mg
bid × 5 days). Two other subjects received 10 days of
antiviral medication (one prophylaxis dosage and one
treatment dosage), and 6 were not treated. Among sub-
jects from whom sequential samples were collected,
virus was detected by rtRT-PCR in NW/TS samples for
up to 15 days after symptom onset. Fourteen subjects
(47%) were culture-positive when initially tested, and ap-
proximately one-third of rtRT-PCR-positive samples col-
lected after enrollment yielded virus in tissue culture.
One subject with a negative culture on day 2 of illness
became culture-positive on day 3 (SUBID009). All
culture-positive samples were collected within the first
week of illness, and all culture-positive samples were
also positive by rtRT-PCR. None of the isolates for
which sequence data are available had mutations indicat-
ing resistance to oseltamivir or zanamivir, including iso-
lates recovered while on therapy (SUBID002, SUBID005,
SUBID009 and SUBID037) and the isolate collected
from subject SUBID012 after failed prophylaxis. No se-
quence data are available from the day 14 and 15 sam-
ples collected from subjects SUBID015 and SUBID025,
respectively.
Serum HAI and neutralizing antibody responses are
shown in Table 2. Of the 30 subjects with confirmed in-
fections, 26 provided acute and/or convalescent blood
samples for antibody assays: 15 provided acute andconvalescent samples; 10 presented at least 2 weeks after
illness onset and donated convalescent sample(s) only;
and 1 subject provided only an acute sample. Eleven
(73%) of those with paired samples developed ≥4-fold
rise in serum HAI and/or neutralizing antibody titer;
and 3 additional subjects with paired samples had an
HAI and/or neutralizing antibody titer of at least 20 in
one or both samples. Twenty of 26 subjects (77%) had
an HAI and/or neutralizing antibody titer ≥ 40 in acute
and/or convalescent sample(s). Only 1 subject failed to
develop a convalescent HAI or neutralizing antibody
titer ≥ 20 after infection.
Clinical features of confirmed infections
Most subjects (N=23) reported close contact with a con-
firmed or probable case prior to the onset of illness; most
of these (N=17) were contact with a classmate in school
or daycare. Three were exposed to an infected household
member; one each reported exposure to a co-worker, oc-
cupational exposure, or contact with multiple cases. Seven
subjects could not identify a likely source of their infec-
tion. Among the 30 subjects with confirmed infections,
two separate clusters were identified. One was an outbreak
of A(H1N1)pdm09 influenza in a local elementary school,
and the other was an outbreak among students studying
and working together at a regional university.
Symptoms and signs reported by subjects with confirmed
A(H1N1)pdm09 infections are summarized in Table 3. The
most common symptom was cough, reported by 29/30
subjects. The median duration of cough was 10 days; how-
ever, cough persisted for up to 32 days after the onset of ill-
ness for one subject. Twenty-eight (93%) subjects reported
fever. Feverishness, chills, fatigue, lethargy, myalgia, head-
ache, rhinitis, and sore throat were reported by a majority
of subjects. Nausea, diarrhea and vomiting were reported
by 40%, 23% and 20%, respectively.
All enrolled subjects recovered from their infection.
Table 4 summarizes illness outcomes for subjects with
confirmed infections. Most subjects (77%) reported
Table 3 Clinical features of confirmed A(H1N1)pdm09 infections
Symptom
Severity Duration
None Mild Moderate Severe Any Duration (days) Mean Duration (days) Median (Min, Max)
Elevated Temperature (Max) 2 (7) * 8 (27) 8 (27) 12 (40) 28 3.2 3.0 (1, 8)
Feverishness 3 (10) 6 (20) 13 (43) 8 (27) 27 3.6 3.0 (1, 6)
Fatigue (Malaise) 4 (13) 4 (13) 12 (40) 10 (33) 26 5.4 4.0 (2, 16)
Irritability 19 (63) 6 (20) 3 (10) 2 (7) 11 4.6 4.0 (2, 15)
Lethargy 15 (50) 3 (10) 7 (23) 5 (17) 15 4.5 4.0 (2, 10)
Myalgia/Body ache 13 (43) 6 (20) 9 (30) 2 (7) 17 3.9 3.0 (2, 7)
Headache 6 (20) 7 (23) 11 (37) 6 (20) 24 3.1 3.0 (1, 6)
Stuffy/Runny nose 11 (37) 11 (37) 8 (27) 0 19 8.4 6.0 (1, 23)
Nausea 18 (60) 7 (23) 5 (17) 0 12 3.0 3.0 (1, 6)
Vomiting 24 (80) 3 (10) 2 (7) 1 (3) 6 1.8 1.5 (1, 4)
Diarrhea 23 (77) 5 (17) 1 (3) 1 (3) 7 3.3 3.0 (1, 10)
Chills 11 (37) 6 (20) 10 (33) 3 (10) 19 2.9 3.0 (1, 7)
Sore throat 14 (47) 9 (30) 6 (20) 1 (3) 16 3.5 3.0 (1, 7)
Cough 1 (3) 11 (37) 16 (53) 2 (7) 29 11.2 10.0 (4, 32)
Shortness of breath 25 (83) 4 (13) 1 (3) 0 5 4.0 4.0 (2, 6)
Wheezing 25 (83) 4 (13) 1 (3) 0 5 3.4 3.0 (1, 6)
Earache 29 (97) 0 1 (3) 0 1 7.0 7.0 (7, 7)
Sinus fullness/Facial pain 27 (90) 2 (7) 1 (3) 0 3 7.0 5.0 (1, 15)
Other symptoms 11 (37) 8 (27) 6 (20) 5 (17) 19 4.4 3.0 (2, 21)
*Number (percent).
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evaluated in the emergency room. One 24-year-old male
who had a history of childhood asthma experienced a
syncopal episode on day 4 of illness (SUBID025). Evalu-
ation in a local emergency room (ER) was consistent
with a vasovagal episode secondary to dehydration. The
same subject was evaluated in the ER 4 days later with a
complaint of hemoptysis attributed to acute bronchitis.Table 4 Clinical outcomes for patients with confirmed A
(H1N1)pdm09 infections
Clinical outcomes N (%)
Medically Attended Visits
Physician's office 23 (77)
Emergency room 3 (10)
Missed School or Work 21 (70)
Mean number of days 4
Median (Min, Max) 3 (1, 10)
Medical Diagnoses
Febrile acute respiratory disease 29 (97)




Other diagnoses/complications 2 (7)Initial chest radiograph demonstrated mild pulmonary
vascular congestion, and a follow-up chest radiograph
4 days later was normal. This subject was treated with 2
courses of antibiotics and did not receive antiviral ther-
apy. A rapid test for influenza was negative on day 8 of
illness; rtRT-PCR was positive on respiratory samples on
days 12 (time of study enrollment) and 15 after illness
onset. One 7-year-old child with asthma was seen in the
emergency room for a high fever (104.1°F) and ‘talking
nonsense in her sleep’; she was treated with oseltamivir
and amoxicillin. Finally, one 2-month-old female infant
was evaluated in the ER for fever. No subjects required
hospitalization for their illness. Seven subjects did not
seek medical attention: 4 of these were part of the 2
clusters of illness; 2 were family members of medically-
attended cases; and one was a BCM employee who was
aware of the study.
Discussion and conclusions
We characterized the clinical, virological and serological
responses among 30 ambulatory children and adults,
most of whom were previously healthy. The most com-
monly reported underlying health condition was asthma.
Clinical features of illness were similar to those de-
scribed previously among outpatients who were index
cases enrolled in prospective studies of household trans-
mission of A(H1N1)pdm09 infections [6,7]. Of interest
Table 5 Numbers of subjects from whom the indicated types of samples were collected during the rapid research
































Yes 43* 19 3 6** 17 41 32
No 8 0 0 34 100 0 2
Abbreviations: NW=nasal wash; NPS=nasopharyngeal swab; TS=throat swab; PBMC=peripheral blood mononuclear cells.
*Two of these had significant increases in serum antibody levels without virological confirmation. All subjects have paired sera, but some have only
convalescent PBMCs.
**One subject has convalescent PBMCs without serum.
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tions remained positive for up to 2 weeks in 2 subjects,
one of whom had received a full course of oseltamivir.
As noted by others, PCR was considerably more sensi-
tive than culture [8], and remained positive for a longer
period of time. While isolates with the H275Y mutation
have been detected in patients who developed illness
while receiving prophylactic oseltamivir [9], our subjects
did not have evidence of this mutation
Availability of supporting data
The main goal of this study was to collect blood and re-
spiratory samples that could be used to characterize vi-
ruses and host immune responses as the A(H1N1)pdm09
pandemic unfolded. Three sites were involved in the sam-
ple collection protocol: Baylor College of Medicine;
Centro para Vacunas en Desarrollo-Chile; and the Univer-
sity of Texas School of Public Health in Brownsville, TX
(see references [10,11] for descriptions of the Brownsville
outbreak), During the study a number of viruses were se-
quenced and the information made publically available in
GenBank by late 2009 (GenBank accession numbers
for the Houston isolates are CY051903, CY051926,
CY052959, CY053173, CY053366, CY087216, CY087223).
Selected samples were deposited at the National Institutes
of Health (NIH) Biodefense and Emerging Infections Re-
search Resources Repository (BEI). Two adult subjects
with moderate to high levels of antibodies in convalescent
sera had large volumes of blood collected for the prepar-
ation of antibody pools. Aliquots of these pools were used
to standardize HAI and neutralizing antibody assays
performed on sera collected from participants in clinical
trials of A(H1N1)pdm09 vaccines conducted by the
NIH and industry. Aliquots of sera used for assay
standardization are available upon request from BEI
(http://www.beiresources.org/Catalog.aspx; Catalog Nos.
NR-18964 and 189655). Aliquots of PBMCs that can be
used for characterization of cellular immune responses to
A(H1N1)pdm09 and other influenza viruses have been
submitted to the above-mentioned repository. Virusisolates, respiratory samples (nasal wash, throat swab,
nasopharyngeal swabs and/or nasal swabs), serum and
stool samples collected from A(H1N1)pdm09 -infected
subjects and subjects without confirmation of A(H1N1)
pdm09 infection are also available for use by qualified in-
vestigators, upon request (see Additional file 1, contact
dmidresources@niaid.nih.gov for additional information).
The numbers and types of samples collected during the
study that are available for use by qualified investigators
are summarized in Table 5. Finally, additional NIAID-
funded A(H1N1)pdm09 reagents/materials are available,
as follows: Virus isolates; vaccines (monovalent and triva-
lent formulations); monoclonal antibodies against HA and
NP; polyclonal convalescent human sera; ferret immune
sera panels; BPL-inactivated HA; recombinant HA and
NA; Gateway clone set (E. coli); peptide arrays; and gen-
omic RNAs (HA, NA, NP, matrix, NS1, NS2, PA, PB1 and
PB2). These reagents are available by ordering directly
from the BEI link shown above. Note that researchers do
not need to have NIH funding to access these reagents,
and the reagents available in the repository are provided at
no cost to the researchers.
Additional file
Additional file 1: Specimen listing for rapid research response protocol.
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